T. Rowe Price(US:TROW) Globenewswire·2026-03-20 14:48Core Insights - Longeviti Neuro Solutions has appointed Robert W. Sharps, CEO of T. Rowe Price Group, to its Board of Directors, indicating a strategic move to enhance governance and growth [1][4][6] Company Overview - Longeviti Neuro Solutions is a neurotechnology company focused on developing advanced implantable and AI-enabled solutions for neurological health, including the ClearFit AI™, the first Acoustic Brain Interface (ABI)™ [1][7] - The company aims to improve the understanding and treatment of neurological conditions while supporting long-term brain health and human performance [4][7] Leadership and Expertise - Robert W. Sharps brings over 30 years of leadership experience in global asset management and corporate governance, overseeing more than $1.5 trillion in assets at T. Rowe Price [2][5] - His appointment is expected to strengthen Longeviti's strategic planning, governance, and partnerships as the company scales its operations [4][6] Product and Technology Development - Longeviti is known for its FDA-cleared products and has full in-house manufacturing capabilities, with over 50 patents worldwide and products approved for use in over 120 hospitals globally [8] - The company has successfully used its neurosurgical implants in more than 4,000 patients, showcasing its impact in the field of neurotechnology [8]